Finally, the possibility to pharmacologically modulate spastin levels opens the way to potential clinical implications also in promoting axon regeneration after nerve injury (6, 44) and in neurodegenerative diseases associated to spastin dysfunctions, such as Alzheimer’s disease (45, 46). The gene discussed is SPAST; the disease is early-onset autosomal dominant Alzheimer disease.